
Critical Reviews in Oncology/Hematology 33 (2000) 1–6

**The role of p53-target genes in human cancer**

Takashi Tokino¹, Yusuke Nakamura*

Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai Minato-ku, Tokyo 108-8639, Japan

Received 1 December 1998; received in revised form 1 September 1999; accepted 11 October 1999

---

### Contents

1. p53 Mutations in human cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1. p53 Mutations in human cancer

The p53 gene is the most frequent target of genetic alteration yet identified in human cancers [1]. Wild-type p53 normally functions as a tumor suppressor gene; cells in which p53 is inactivated are known to have a selective growth advantage. Many studies have supported a proposed model for explaining the multiple physiological functions attributed to p53 (reviewed by Ref. [2]). According to this model, wild-type p53 binds to specific genomic sites as a tetramer and stimulates expression of downstream genes that negatively control growth and/or invasion.

Normal p53 function can be lost in a variety of ways, most commonly by loss of a chromosomal region containing one allele of the gene (or of entire chromosome 17p) and a subtle mutation involving the other allele. This scenario fits the ‘two-hit’ model proposed by Knudson [3] for the definition of what came to be known as tumor suppressor genes. Inactivation of both alleles of p53 has been documented in a large number of human cancers, including tumors arising in the colon, brain, lung, liver and bladder. However, in some cases a missense mutation occurring in one allele of p53 is sufficient to inactivate p53 function, when such an event increases the proportion of hetero-tetramers that contain both mutant and wild-type p53 molecules; the chimeric complexes cannot activate transcription of target genes. This ‘dominant-negative’ effect may be exacerbated by the increased stability (and therefore higher intracellular concentration) of the mutant protein compared with that of the wild-type p53 protein. Other mechanisms are also known. For example, in cervical cancers the expression of E6 from certain types of human papilloma virus (HPV), including types HPV16 and HPV18, results in functional inactivation of p53 through binding and rapid degradation [4]. In soft-tissue sarcomas, amplification of MDM2 creates a similar loss of functional p53 through binding and subsequent degradation of the p53 protein [5–8].

Recently, p53 has also been identified as a physiological substrates of ATM [34, 35]. The gene encoding the ATM is mutated in the human disease ataxia telangiectasia, and this effect causes symptoms that include genetic instability and a predisposition to cancer. The ATM protein is a member of family of proteins with similarity to phosphatidylinositol-3 kinases. The ATM phosphorylation of p53 on serine-15 is the same as the one phosphorylated in vivo in response to DNA damage.

2. p53 As a transcriptional activator

Several biological functions of p53 have been described, including induction of G1 arrest or apoptosis following DNA damage or other cellular insults, maintenance genomic stability, and inhibition of angiogenesis. Biochemically, p53 has been shown to bind DNA in a sequence-specific fashion [9] and to activate transcription of genes containing a consensus binding site in their 5′-or 3′-flanking regions or in an intron; these DNA sequences are likely to function as transcriptional enhancers. Therefore, many of the biological activities of p53 are likely to result from transcriptional activation of downstream genes which carry out a variety of functions. In this connection, expression of the p21WAF1/CIP1 gene, one of the downstream targets of p53, can inhibit the growth of a variety of tumor-cell lines in vitro, presumably because its protein product can bind to and inhibit the cyclin-dependent kinases required for completion of the cell cycle [10]. p53-binding sites within or adjacent to other genes (GADD45, MDM2, BAX, cyclinG, IGF-BP3, GML, P2XM, BAI1, 14-3-3σ) have also been documented, and some of those genes may modulate or mediate p53 effects.

3. Strategies for identifying p53-target genes

Some of the genes mentioned above became candidates for p53-targets after investigators found that they bore some relationship to p53 expression. Two other strategies have been used to identify biologically important genes that are transcriptionally regulated by p53. The first of these approaches involved subtractive hybridization and differential screening. These techniques can successfully detect p53-target genes that are expressed in relative abundance. However, identifying p53-regulated genes that are expressed less abundantly or in a tissue-specific manner has proven to be difficult. Another strategy was therefore designed to identify p53-target genes, based on the idea that such genes must contain p53-binding sites in their promoter regions or within their introns. Tokino et al. [11] used a yeast system (Saccharomyces cerevisiae) to identify human genomic sequences, ‘p53-tagged sites,’ that activate transcription from an adjacent reporter gene in a p53-dependent manner.

4. Screening for p53-tagged sites

The product of the p53 gene binds to DNA and activates transcription from promoters containing the consensus binding site defined by El-Deiry et al. [12], 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′. This mechanism is probably responsible for the variety of biological effects attributed to p53. However, the total number and the

nature of human genomic sites with which p53 can functionally interact is unknown. A total of 57 different p53-tagged sites were identified in the experiments alluded to above, and we predict that 200–300 such sites are present in the human genome. Almost all p53-target genes identified so far in this way contain two adjacent copies of the consensus sequence. Spacing between the copies is critical for sequence-specific transcriptional activation in vivo [11]. We have since refined the nature of the genomic sequences likely to be most important for p53-mediated tumor suppression, by isolating cosmids containing these p53-binding sites and identifying exon-like fragments through computer analysis. Genes in proximity to p53-binding sequences were considered to be strong candidates for induction by p53. We confirmed that expression of several such genes is indeed regulated by wild-type p53 [13–17].

### 5. p53-Target genes

p53-Responsive elements identified in our experiments are included in the gene encoding the MDM2 protein, which negatively regulates p53 function; the gene encoding proliferating-cell nuclear antigen (PCNA) which is implicated in DNA replication and nucleotide excision repair in vitro; the GADD45 gene, encoding a protein that binds to PCNA; the p21 WAF1/CIP1 gene, encoding a 21-kd protein that inhibits the kinase activity of the cdk2-cyclin complex required for transition from Gl to S phase in the cell cycle; the IGF-BP3 gene, encoding a protein binding to IGF1, a negative regulator of cell proliferation; the bax gene, whose product is involved in the regulation of apoptosis; and the gene encoding cyclin G, whose function is unclear. A consensus sequence containing two 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′ elements separated by, at most, a couple of nucleotides, have been identified in the promoter and/or an intronic region of each of these genes.

#### 5.1. Negative regulation of p53: MDM2

The Mdm2 oncogene was originally identified as one of several genes contained in a murine double-minute chromosome present in a derivative of transformed 3T3 cells. The transcription-activating function of p53 is eliminated by interaction with the MDM2 gene product [5, 18], because MDM2 promotes rapid degradation of a phosphorylated form of p53 [7, 8]. On the other hand, p53 activates expression of the mdm2 gene in an autoregulatory feedback loop [18]. MDM2 is amplified in 30–40% of human sarcomas [6]; this observation indicates that inhibition of p53 function by over-expression

of MDM2 plays a crucial role in development of many sarcomas. Mdm2-null mice die early in development, but mice deficient for both Mdm2 and p53 develop normally and are viable. Rescue of the mdm2(−/−) lethality in a p53-null background suggests that negative regulation of p53 is a critical function of MDM2 in vivo [19, 20].

#### 5.2. Cell-cycle control: p21 WAF1/CIP1, 14-3-3 σ, cyclin G

Using a subtractive-hybridization approach, El Deiry et al. [21] identified WAF1 (wild-type p53-activated fragment 1), whose induction was associated with expression of wild-type p53. p53 transcriptionally activates the gene encoding the 21-kd WAF1 protein. Simultaneously, WAF1 was discovered as an inhibitor of cyclin-dependent kinase, CIP1 [10]. The combined results suggested a direct link between p53, G1 arrest, and negative regulation of the kinases required for G1-S transition.

A gene called 14-3-3 σ was found through quantitative analysis of expression patterns in colorectal-cancer cell lines. This gene is strongly induced by gamma irradiation and other DNA-damaging agents [22]. Induction of 14-3-3 σ is mediated by a p53-responsive element located 1.8 kb upstream of its transcription start site. As the fission-yeast homologues of 14-3-3, rad24 and rad25, mediate similar checkpoint effects, it appears that a molecular mechanism for G2/M control that is conserved throughout eukaryotic evolution is regulated in human cells by p53.

Through a PCR-based differential screening approach, cyclin G was identified as a novel transcriptional target of p53 [23]. Cyclin G mRNA was rapidly induced by p53 in a mouse temperature-sensitive leukemic cell line and in mouse embryonic fibroblasts (MEF) after gamma-irradiation [23]. However, the function of cyclin G remains unclear.

#### 5.3. DNA replication and repair: GADD45

Several growth-arrest and DNA damage-inducible (or gadd) genes were initially isolated on the basis of induction after DNA damage in Chinese hamster ovary cells. The gadd45 and gadd153 genes in particular are rapidly induced by DNA-damaging agents. Induction of human GADD45 by ionizing radiation depends on normal function of p53, which binds to an intronic consensus element in the gadd45 gene [24]. GADD45 stimulates DNA excision repair in vitro and inhibits entry of cells into S phase. These observations have established GADD45 as a link between the p53-dependent cell checkpoint and DNA repair.

5.4. Cell proliferation: IGF-BP3

A differential-cloning approach identified the gene encoding insulin-like growth factor-binding protein 3 (IGF-BP3) as a novel p53-regulated target [25]. Induction of expression by wild-type (but not mutant) p53 is associated with enhanced secretion of an active form of IGF-BP3 that is capable of inhibiting mitogenic signalling by the insulin-like growth factor IGF-1 [25]. IGF-BP3 may link p53 to as yet uncharacterized autocrine/paracrine signalling pathways.

5.5. Apoptosis: BAX, GML, P2XM, Killer/DR5, PAG608

Bcl-2 and Bax are homologous proteins that have opposing effects on cell life and death; Bcl-2 serves to prolong cell survival and Bax accelerates apoptosis. Bcl-2 and Bax proteins can form heterodimers in cells, and their interaction appears to be critical to the ability of Bcl-2 to block cell death. Miyashita and Reed [26] found p53-binding sites in the promoter upstream of the bax gene. In co-transfection assays using p53-deficient tumor cell lines, these authors demonstrated that a wild-type (but not mutant) p53-expression plasmid could transactivate a reporter-gene plasmid that utilized the bax gene promoter. However, Knudson et al. [27] showed that cells from Bax-deficient mice were proficient in mounting a response to the p53-dependent apoptosis induced by ionizing radiation, suggesting that bax is not required for p53-dependent apoptosis of thymocytes.

A subtractive-hybridization screening protocol, using a library enriched for doxorubicin-induced transcripts derived from chemosensitive PA-1 ovarian teratocarcinoma cells, identified a novel transcript designated KILLER [28]. The KILLER gene was induced by doxorubicin only in cells with wild-type p53 status. KILLER has been independently identified as DR5, TRAIL-2, and TRICK2. KILLER/DR5 encodes a cell-surface protein that contains a cytoplasmic death domain and bears a high degree of homology to members of the TNFR family. KILLER/DR5 may represent a potential mechanism by which DNA damage can lead to p53-dependent apoptosis.

Through cloning of functional p53-binding sites (p53-tagged sites) from the human genome, Tokino et al. [11] identified several novel genes inducible by over-expression of wild-type p53. Among them were GML (GPI-anchored molecule-like protein), whose predicted product showed a high degree of homology to the family of glycosyl-phosphatidylinositol (GPI)-anchored membrane proteins. The GML gene is regulated in a p53-dependent manner; its expression level is correlated with the sensitivity of esophageal cancer cells to anticancer drugs [13], and the gene product enhances apoptosis.

tosis induced by anti-cancer drugs and gamma-irradiation [16, 29]. P2XM (P2X specifically expressed in skeletal muscle) is another gene isolated by this approach [15]. It showed significant homology to members of the P2X family of ATP-gated ion channels. Expression of P2XM was reduced or lost in several sarcoma cell lines, and an aberrant splicing variant that would encode a deficient protein because it lacked part of exon 1 was predominant in some of the sarcoma cell lines [15].

An additional p53-target gene in the apoptosis category, PAG608, encoding a nuclear zinc finger protein, was identified by differential display. The product of PAG608 appears to localize preferentially to nucleoli [30]. Transient over-expression of PAG608 in human tumor-derived cells leads to distinctive changes in nuclear morphology, and can promote apoptosis.

5.6. Angiogenesis inhibition: TSP-1, BAI1

As normal cells progress toward malignancy, they must switch to an angiogenic phenotype to attract the nourishing vasculature that they depend on for their growth. This switch was found to coincide with loss of the wild-type allele of p53 and to be the result of reduced expression of thrombospondin-1 (TSP-1), a potent inhibitor of angiogenesis, in cultured fibroblasts from patients with Li-Fraumeni syndrome [31]. p53 stimulates the endogenous TSP-1 gene and positively regulates TSP-1 promoter sequences [31]; therefore, in fibroblasts wild-type p53 inhibits angiogenesis through regulation of TSP-1.

Genetic alterations of p53 are associated with neovascularization during progression of a glioma to its more malignant form, glioblastoma. Hence, several genes transactivated by p53 are likely to function as angiogenesis inhibitors. Nishimori et al. isolated another novel p53-inducible gene that encodes a 1584-amino-acid product that contains five thrombospondin type 1 (TSP-type 1) repeats and is specifically expressed in the brain [14]. A recombinant protein corresponding to the TSP-type 1 repeats present in this gene product inhibited in vivo neovascularization induced by bFGF in the rat cornea [14]. We also found that transcripts of this gene, named BAI1 (brain-specific angiogenesis inhibitor 1), were absent or significantly reduced in glioblastoma cell lines, suggesting that BAI1 plays a significant role as a mediator of p53 in inhibiting angiogenesis.

5.7. Cellular stress response: TP53TG1, CSR, PIG3

Recently we established a colon-cancer cell line carrying a wild-type p53 transgene that is inducible under control of the lactose operon [32]. Induction of this transgene by IPTG arrests growth of transfected cells.

To investigate cellular responses related to the p53 signaling pathway leading to growth arrest, we applied a differential display method to screen mRNAs isolated from this cell line and looked for genes whose expression was activated or suppressed after induction of wild-type p53. Subsequent Northern-blot analyses confirmed expression of a novel gene; this cDNA, named TP53TG1 (TP53 target gene 1), contained an open reading frame of 270 nucleotides encoding 90 amino acids [32]. Under conditions of cellular stress (ultraviolet irradiation, or exposure to bleomycin or cisplatin), expression of TP53TG1 was induced in a wild-type p53-dependent manner, indicating that this gene is likely to play an important role in the p53 signaling pathway and may function in response to cellular damage [32].

By cloning functional p53-binding sites from the human genome as described above, Han et al. [17] also isolated a p53-inducible macrophage scavenger receptor-like gene, CSR (cellular stress response) from chromosomal band 8q21. The p53-binding site was located in intron 2. In normal fibroblasts, CSR expression was elevated by exposure to UV irradiation or hydrogen peroxide, but as DNA-damaging agents such as adriamycin and bleomycin did not affect the expression of CSR, transcription of this gene appears to be regulated not only by p53 but by unidentified factors as well.

To evaluate the patterns of expression following over-expression of wild-type p53, Polyak et al. [33] invoked SAGE (serial analysis of gene expression), a technique that allows quantitative evaluation of cellular mRNA populations. Of 7202 transcripts identified, only 14 (0.2%) were markedly increased in p53-expressing cells compared with control cells. Strikingly, many of those 14 genes encoded proteins that could generate or respond to oxidative stress, notably PIG3 (p53-induced gene 3). A homologue of the predicted PIG3 product is implicated in apoptosis in plant meristems [33]. These observations suggest that the cumulative induction of p53-induced genes was thought to mediate the p53 induction of apoptosis.

In normal cells, DNA damage triggers several signal transduction pathways that result either in DNA repair coupled with growth arrest, or in apoptosis. The differential response to p53 has not been accounted for. A connection of such pathways is controlled by p53 through leading to the activation of downstream genes. Although p53 is mutated in a large proportion of human cancers, genetic alterations of p53-target genes were infrequently identified except MDM2 amplification in soft tissue tumors. p53-target genes in combination may lead to apoptosis in selected cellular conditions. As the clinical manifestation exhibited by p53 mutation can not be attributed to one of the target genes, a large number of targets of p53 may remain to be identified and characterized.


Reviewers

This paper was reviewed by Dr Andrew P. Feinberg, Department of Medicine, Oncology and Molecular Biology & Genetics, Johns Hopkins University School of Medicine, Ross Bldg., Room 1064, 720 Rutland Avenue, Baltimore, MD 21205, USA; Jonas Bergh, MD, PhD, Department of Oncology, Radiumhemmet, SE-171 76 Stockholm, Sweden and Jan G.M. Klijn, MD, PhD, Professor of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek, NL-3008 AE Rotterdam, The Netherlands.


References

[1] Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 Mutation in human cancers. Science 1991;253:49–53.
[2] Vogelstein B, Kinzler KW. p53 Function and dysfunction. Cell 1992;70:523–6.
[3] Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437–43.
[4] Scheffner M, Werness BA, Huibregste JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129–36.
[5] Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237–45.
[6] Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80–3.
[7] Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296–9.
[8] Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;387:299–303.
[9] Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1991;252:1708–11.
[10] Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinases. Cell 1993;75:805–16.
[11] Tokino T, Thiagalingam S, El-Deiry WS, Waldman T, Kinzler KW, Vogelstein B. p53 Tagged sites from human genomic DNA. Human Mol Genet 1994;3:1537–42.
[12] El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nature Genet 1993a;1:45–9.
[13] Furuhata T, Tokino T, Urano T, Nakamura Y. Isolation of a novel GPI-anchored gene specifically regulated by p53; correlation between its expression and anti-cancer drug sensitivity. Oncogene 1996;13:1965–70.
[14] Nishimori N, Shiratsuchi T, Urano T, et al. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene 1997;15:2145–50.
[15] Urano T, Nishimori H, Han HJ, et al. Cloning of P2XM, a novel human P2X receptor gene regulated by p53. Cancer Res 1997;57:3281–7.
[16] Kagawa K, Inoue T, Tokino T, Nakamura Y, Akiyama T. Overexpression of GML promotes radiation-induced cell cycle arrest and apoptosis. BBRC 1997;241:481–5.
[17] Han HJ, Tokino T, Nakamura Y. CSR, a scavenger receptor-like protein with a protective role against cellular damage caused

by UV irradiation and oxidative stress. Human Mol Genet 1998;7:1039–46.

[18] Wu X, Bayle JH, Olson D, Levine J. The p53-mdm2 autoregulatory feedback loop. Genes Dev 1993;7:1126–32.

[19] Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995;378:206–8.

[20] de Oca Luna RM, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995;378:203–6.

[21] El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993b;75:817–25.

[22] Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 (σ[sigma]) is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997;1:3–11.

[23] Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 1994;13:4816–22.

[24] Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587–97.

[25] Buckbinder L, Talbott R, Velasco-Miguel S, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646–9.

[26] Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293–9.

[27] Knudson CM, Tung KS, Tourtellotte WG, Brown GA, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995;270:96–9.

[28] Wu GS, Burns TF, McDonald III ER, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141–3.

[29] Kimura Y, Furuhata T, Shiratsuchi T, et al. GML sensitizes cancer cells to Taxol by induction of apoptosis. Oncogene 1997;15:1369–74.

[30] Israeli D, Tessler E, Haupt Y, et al. A novel p53-inducible gene, PAG 608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J 1997;16:4384–92.

[31] Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582–4.

[32] Takei Y, Ishikawa S, Tokino T, Muto T, Nakamura Y. Isolation of a novel TP53 target gene from a colon cancer cell line carrying a highly regulated wild-type TP53 expression system. Genes Chromosomes Cancer 1998;23:1–9.

[33] Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997;389:300–5.

[34] Banin S, Moyal L, Shieh SY, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 1998;281:1674–7.

[35] Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 1998;281:1677–9.

Biography

Takashi Tokino: 1989, Osaka University, Ph.D; 1989–1995, Research associate, Cancer Institute, Tokyo; 1991–1994, Postdoctoral fellow, Johns Hopkins University; 1995–1997, Associate Professor, Institute of Medical Science, the University of Tokyo; 1997 to present, Professor, Cancer Research Institute, Sapporo Medical University School of Medicine, Sapporo.
